Trial · NCT05171647
Outcomes20
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | ORR as Determined by the IRF, According to LRC Using PET-CT or CT Scans in ITT Population | Up to 32 months | |||
| SECONDARY | ORR as Determined by the Investigator, According to LRC Using PET-CT or CT Scans in ITT Population | Up to approximately 58 months | |||
| SECONDARY | Duration of Response (DoR) as Determined by the IRF, According to LRC Using PET-CT or CT Scans | Up to 32 months | |||
| SECONDARY | DoR as Determined by the Investigator, According to LRC Using PET-CT or CT Scans | Up to approximately 58 months | |||
| SECONDARY | Overall Survival (OS) | Up to 32 months | |||
| SECONDARY | PFS as Determined by the Investigator, According to LRC Using PET-CT or CT Scans | Up to approximately 58 months | |||
| PRIMARY | Objective Response Rate (ORR) as Determined by the Independent Review Facility (IRF), According to Lugano Response Criteria 2014 (LRC) Using Positron Emission Tomography-computed Tomography (PET-CT) or CT Scans in Interim Analysis Population (IAP) | Up to approximately 23.8 months | IAP population included the first 178 randomized participants, with participants grouped according to their assigned treatment. | percentage of participants | NUMBER |
| PRIMARY | Progression-free Survival (PFS) as Determined by the IRF, According to LRC Using PET-CT or CT Scans | Up to 32 months | Intent-to-treat (ITT) population included all randomized participants, with participants grouped according to their assigned treatment. | months | MEDIAN |
| SECONDARY | Complete Response Rate (CRR) as Determined by the IRF, According to LRC Using PET-CT or CT Scans | Up to approximately 58 months | |||
| SECONDARY | CRR as Determined by the Investigator, According to LRC Using PET-CT or CT Scans | Up to approximately 58 months | |||
| SECONDARY | Duration of Complete Response (DOCR) as Determined by the IRF, According to LRC Using PET-CT or CT Scans | Up to 32 months | |||
| SECONDARY | DOCR as Determined by the Investigator, According to LRC Using PET-CT or CT Scans | Up to approximately 58 months | |||
| SECONDARY | Time to Deterioration in Physical Functioning (PF), as Measured by the European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire-Core 30 (EORTC QLQ-C30) | Up to approximately 58 months | |||
| SECONDARY | Time to Deterioration in Fatigue Scale, as Measured by the EORTC QLQ-C30 | Up to approximately 58 months | |||
| SECONDARY | Time to Deterioration in Lymphoma Symptoms, as Measured by Functional Assessment of Cancer Therapy- Lymphoma Questionnaire (FACT- Lym LymS) | Up to approximately 58 months | |||
| SECONDARY | Number of Participants With Adverse Events (AEs) | Up to approximately 58 months | |||
| SECONDARY | Number of Participants With Cytokine Release Syndrome (CRS) With Severity Determined by the American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale | Up to approximately 58 months | |||
| SECONDARY | Number of Participants With Dose Interruptions, Dose Reductions and Study Treatment Discontinuation Due to AEs | Up to approximately 58 months | |||
| SECONDARY | Dose Intensity of Mosunetuzumab | Up to approximately 58 months | |||
| SECONDARY | Change From Baseline in Peripheral Neuropathy (PN), as Measured by the Functional Assessment of Cancer Therapy-Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) | Up to approximately 58 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05171647/outcomes